<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497870</url>
  </required_header>
  <id_info>
    <org_study_id>H-40351</org_study_id>
    <nct_id>NCT04497870</nct_id>
  </id_info>
  <brief_title>Peppermint Oil Pharmacokinetics/Dynamics</brief_title>
  <official_title>Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In children 7-12 years of age with functional abdominal pain (n=42) determine:&#xD;
&#xD;
      Aim 1 - To examine and characterize the threshold of the exposure (PK) vs. response (PD)&#xD;
      relationship of PMO (menthol)&#xD;
&#xD;
      Aim 2 - PD of PMO as assessed by:&#xD;
&#xD;
        1. Microbiome composition (16S RNA sequencing)&#xD;
&#xD;
        2. Transit rate/contractile activity (using the SmartPill®) Aim 3 - Evaluate the potential&#xD;
           association between PD response and clinical symptoms (abdominal pain and stooling&#xD;
           pattern via validated diary), psychosocial distress (anxiety, depression, somatization),&#xD;
           and characterize potential side effects (questionnaire)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An initial single-dose PK study will be carried out. Forty-two children (n=21 per dose) will&#xD;
      be randomized to receive approximately 10.9 mg·kg-1·d-1 of PMO or to receive approximately&#xD;
      18.2 mg·kg-1·d-1 (1.67-fold the median dose).&#xD;
&#xD;
      Following the single-dose PK study, a PD study will be carried out wherein the subjects will&#xD;
      receive their assigned dose of PMO for 7 days.&#xD;
&#xD;
      At baseline (before the PK study) and after the PK study (i.e., during the PD study),&#xD;
      subjects will keep a pain and stooling diary, collect stool for microbiome analysis, and&#xD;
      swallow a SmartPill to measure gut motility and transit time. At baseline only, anxiety,&#xD;
      depression, somatization will be measured. During the PD study, any side effects will be&#xD;
      recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of peppermint oil</measure>
    <time_frame>2 weeks</time_frame>
    <description>Area under the curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut Microbiome composition</measure>
    <time_frame>2 weeks</time_frame>
    <description>Gut microbiome composition as determined by 16S sequencing as a consequence of the administration of peppermint oil at the two doses given.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut transit time</measure>
    <time_frame>2 weeks</time_frame>
    <description>Gut transit time as a consequence of the administration of peppermint oil at the two doses given.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut contractility</measure>
    <time_frame>2 weeks</time_frame>
    <description>Gut contractility as a consequence of the administration of peppermint oil at the two doses given.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>540 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peppermint oil at a dose of 180 mg thrice daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peppermint oil at a dose of 180 mg five times daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peppermint oil</intervention_name>
    <description>Administration of peppermint oil at one of two daily doses.</description>
    <arm_group_label>540 mg</arm_group_label>
    <arm_group_label>900 mg</arm_group_label>
    <other_name>menthol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children ages 7-12 years who are able to assent to the procedures&#xD;
&#xD;
          -  Able to complete the diaries which have been validated for use in this age range&#xD;
&#xD;
          -  The history and medical evaluation reveal no organic reason for the abdominal pain&#xD;
&#xD;
          -  The child has abdominal pain that meets the definition of FAP according to pediatric&#xD;
             Rome IV&#xD;
&#xD;
          -  Ability to understand study procedures and to comply with them for the entire length&#xD;
             of the study&#xD;
&#xD;
          -  Childrens' body weights will not vary by more than 10-15 kg (so that dose per kg is&#xD;
             comparable within the two dosing groups)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past bowel surgery&#xD;
&#xD;
          -  Documented GI disorders (e.g., Crohn's disease)&#xD;
&#xD;
          -  A serious chronic medical condition (e.g., diabetes)&#xD;
&#xD;
          -  A weight and/or height &lt; 2 SD for age&#xD;
&#xD;
          -  Chronic conditions with GI symptoms (e.g., cystic fibrosis)&#xD;
&#xD;
          -  Autism spectrum disorder, significant developmental delay, psychosis, depression, or a&#xD;
             history of bipolar disorder&#xD;
&#xD;
          -  Antibiotic/probiotic treatment within 2 mo.&#xD;
&#xD;
          -  Allergy/sensitivity to PMO or its ingredients&#xD;
&#xD;
          -  Inability to swallow the PMO capsule or the SmartPill®&#xD;
&#xD;
          -  Inability to speak English - testing materials are available only in this language&#xD;
&#xD;
          -  Unable to discontinue laxative, prokinetic, or neuromodulator from 3 wk prior to Visit&#xD;
             1 through the end of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Shulman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Charron</last_name>
    <phone>7137980381</phone>
    <email>Heather.Charron@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Nutrition Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Charron</last_name>
      <phone>713-798-0381</phone>
      <email>Heather.Charron@bcm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Robert Shulman, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peppermint oil</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

